March 10, 2022

Chameleon Founder Speaks at 5th annual Gene Therapy for Rare Disorders Conference

Immunology and gene therapy CEO and scientist presents innovative vector modifications at industry summit

The Gene Therapy for Rare Disorders Conference is dedicated to overcoming the unique drug development challenges encountered in transforming gene therapy concepts into reality for rare disease patients in need.

As the gene therapy field strives to strike the balance between clinical efficacy and product safety in the context of mounting regulatory scrutiny, Gene Therapy for Rare Disorders provides in-depth insights from experts who know how to drive clinical progress, optimize manufacturing, and demonstrate the value of gene therapy products to regulators, payers, and patients.

In her segment, “Investigating the Promise of Redosing in Gene Therapy with EVADER™” CEO Genine Winslow will speak on Chameleon Biosciences’ innovative EVADER (patent pending) platform which we hope will specialize in giving people with genetic diseases who were previously untreatable the chance to live normal lives. In her presentation, Genine will discuss novel dosing regimens as well as the underlying biology of the human immune response that Chameleon’s EVADER is able to bypass.

For more information on the Gene Therapy for Rare Disorders and Genine’s presentation, visit